secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016068
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007
--------------------------------------------------------------------------------

- Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.
- Cash and short-term investments $354.3M (Dec 31, 2021: $375.0M).
- FDA cleared IND for JANX007 (PSMA-TRACTr) for mCRPC; Phase 1 trial expected 2H 2022.
- IND submission for JANX008 (EGFR-TRACTr) on track for 2H 2022; TROP2-TRACTr IND planned for 2023.
- First TRACIr candidate (PD-L1xCD28) IND-enabling studies ongoing; IND submission expected 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/0000950170-22-016068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/janx-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer